Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.
The Weekly Roundup: April 15-19
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events
ReV Up Your Vitiligo Treatment Strategies
Mobile Health Technologies In Studies of Actinic Keratosis Do Not Compromise Patient Safety, Research Article Says
Brittany Scurto, PA-C: How to Discuss an Integrative Medicine Approach With Patients